AAV Gene Therapy Enabler
Depletion of pre-existing AAV neutralizing antibodies
Pre-clinical/ResearchActive
Key Facts
Indication
Depletion of pre-existing AAV neutralizing antibodies
Phase
Pre-clinical/Research
Status
Active
Company
About MediSieve
MediSieve is a private, pre-revenue biotech founded in 2014, pioneering a magnetic blood filtration platform. Its core technology involves functionalizing magnetic beads to bind specific targets in the blood, which are then removed extracorporeally via a magnetic filter. The pipeline targets acute hyperinflammation (e.g., sepsis, CRS), severe malaria, and enabling AAV gene therapies by depleting neutralizing antibodies. The company represents a novel therapeutic device approach in hematology and critical care.
View full company profile